Description

Cabergoline

Dopamine D2 Receptor Agonist | Ergot-Derived Pharmaceutical Compound

Cabergoline is a long-acting, synthetic ergoline derivative and dopamine D2 receptor agonist used in pharmacological and endocrine research. Its primary biological action involves stimulation of dopamine receptors, particularly D2 receptors, which are important regulators of prolactin secretion and neuroendocrine signaling.

Cabergoline has an established pharmaceutical history and is approved in several jurisdictions for the treatment of hyperprolactinemia, including conditions associated with elevated prolactin levels.

Key Characteristics

  • Product Name: Cabergoline
  • Drug Class: Dopamine receptor agonist
  • Primary Target: Dopamine D2 receptor
  • Chemical Class: Ergoline derivative
  • Pharmacological Area: Endocrinology and neuropharmacology
  • Common Pharmaceutical Strength: 0.5 mg tablet
  • Research Areas: Prolactin regulation, dopamine signaling, endocrine pharmacology, and receptor biology

Mechanism of Action

Cabergoline acts primarily as a dopamine D2 receptor agonist. Dopaminergic signaling through D2 receptors in the pituitary inhibits prolactin secretion, making cabergoline an important compound for studying the relationship between dopamine signaling and endocrine regulation.

Its relatively long duration of action also makes it useful in pharmacokinetic and pharmacodynamic research.

Research Applications

Cabergoline may be investigated in controlled laboratory and pharmacological research involving:

  • Dopamine D2 receptor signaling
  • Prolactin regulation
  • Pituitary endocrine function
  • Neuroendocrine signaling
  • Dopamine pharmacology
  • Receptor-binding studies
  • Pharmacokinetic research
  • Pharmacodynamic studies
  • Drug-interaction research
  • Analytical identification and characterization

Research Advantages

Selective Dopaminergic Activity

Provides a well-characterized pharmacological model for investigating D2-receptor-mediated signaling.

Endocrine Research Utility

Useful for studying dopaminergic regulation of prolactin and related pituitary pathways.

Long-Acting Pharmacology

Its extended pharmacological activity makes it relevant to duration-of-action and pharmacokinetic research.

Established Reference Compound

Cabergoline has extensive pharmaceutical and scientific documentation, making it useful for comparative pharmacological studies.

Analytical Compatibility

Suitable for validated analytical workflows evaluating compound identity, purity, assay, concentration, and stability.

Product Specifications

Specification Details
Product Name Cabergoline
Drug Class Dopamine D2 receptor agonist
Chemical Class Ergoline derivative
Common Strength 0.5 mg
Primary Target D2 dopamine receptor
Main Research Area Endocrine & neuropharmacology
Documentation COA / batch information recommended

Pharmaceutical Applications

Cabergoline is an established prescription medicine used primarily to reduce elevated prolactin levels in patients with hyperprolactinemia and certain associated disorders. Approved indications and formulations vary by jurisdiction.

Quality & Documentation

For legitimate pharmaceutical, laboratory, or analytical applications, relevant documentation may include:

  • Active ingredient identity
  • Assay/purity
  • Strength or concentration
  • Batch or lot number
  • Certificate of Analysis (COA)
  • Stability information
  • Relevant analytical test results

Important Safety & Regulatory Disclaimer

Cabergoline is a pharmacologically active prescription medicine and is not a dietary supplement or general wellness product. It can produce clinically significant effects and adverse reactions, including nausea, dizziness, low blood pressure, and other dopaminergic or cardiovascular effects. Long-term treatment may require specific medical monitoring depending on the clinical situation.

This description is provided for scientific, product-identification, and legitimate research/analytical purposes. It does not provide dosing instructions or recommend non-prescribed use. Human use should follow authorized prescribing information and qualified medical supervision.